Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
Tumour treating fields therapy for glioblastoma: current advances and future directions
O Rominiyi, A Vanderlinden, SJ Clenton… - British journal of …, 2021 - nature.com
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and
continues to portend poor survival, despite multimodal treatment using surgery and …
continues to portend poor survival, despite multimodal treatment using surgery and …
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma
Phenotypic plasticity has emerged as a major contributor to intra-tumoral heterogeneity and
treatment resistance in cancer. Increasing evidence shows that glioblastoma (GBM) cells …
treatment resistance in cancer. Increasing evidence shows that glioblastoma (GBM) cells …
Tumor microenvironment in glioblastoma: Current and emerging concepts
P Sharma, A Aaroe, J Liang… - Neuro-Oncology …, 2023 - academic.oup.com
Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex
system, which in addition to cancer cells, consists of various resident brain and immune cells …
system, which in addition to cancer cells, consists of various resident brain and immune cells …
Glioma: molecular signature and crossroads with tumor microenvironment
L Barthel, M Hadamitzky, P Dammann… - Cancer and Metastasis …, 2022 - Springer
In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …
Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma
Glioblastoma (GBM) tumors consist of multiple cell populations, including self-renewing
glioblastoma stem cells (GSCs) and immunosuppressive microglia. Here we identified …
glioblastoma stem cells (GSCs) and immunosuppressive microglia. Here we identified …
Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications
R Paul, JF Dorsey, Y Fan - Pharmacology & therapeutics, 2022 - Elsevier
Cancer stem cells (CSCs) are a distinct population of cells within tumors with capabilities of
self-renewal and tumorigenicity. CSCs play a pivotal role in cancer progression, metastasis …
self-renewal and tumorigenicity. CSCs play a pivotal role in cancer progression, metastasis …
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling
Radiation therapy (RT) provides therapeutic benefits for patients with glioblastoma (GBM),
but inevitably induces poorly understood global changes in GBM and its microenvironment …
but inevitably induces poorly understood global changes in GBM and its microenvironment …
Neuronal and tumourigenic boundaries of glioblastoma plasticity
Glioblastoma (GBM) remains the most lethal primary brain cancer largely due to recurrence
of treatment-resistant disease. Current therapies are ultimately ineffective as GBM tumour …
of treatment-resistant disease. Current therapies are ultimately ineffective as GBM tumour …
Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors
Malignant stem cells have long been considered a key therapeutic target in leukemia.
Therapeutic strategies designed to target the fundamental biology of leukemia stem cells …
Therapeutic strategies designed to target the fundamental biology of leukemia stem cells …